Valuation
- Market cap
- 9,110,000
- Revenue TTM
- $290,000
- Net income TTM
- $-12,600,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,344.83%
- Debt to equity
- 0.00
Trading
- Volume
- 862,200
- Avg volume
- 329,588
- Day's range
- $0.69 – $0.74
- Shares out
- 12,591,000
- Stochastic %K
- 14%
- Beta
- 1.66
- Analysts
- Strong Sell
- Price target
- $3.73
Company profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers a...
Show more
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 215 948 4119
- Website
- https://aprea.com
- Address
- 3805 Old Easton Road, Doylestown, United States
Latest news
No headlines yet.
